Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
fighting games online
Popular Articles

Obama, Pope Focus On Abortion, 'Life' Issues In First Meeting
In their first meeting, President Obama and Pope Benedict XVI on Friday discussed their views on abortion, embryonic stem cell research and the rights of health care workers to object to procedures and services that go against their beliefs, the Los Angeles Times reports. During a 30-minute discussion, the pope expressed to Obama his beliefs about "the defense and promotion of life and the right to abide by one"s conscience," according to the Vatican. The Times reports that the statement was a "clear reference" to debates over abortion rights, embryonic stem cell research and "conscience" protections for health care providers who refuse care on moral or religious grounds (Chu, Los Angeles Times, 7/11).According to Time, Benedict showed "no intention of papering over differences on what the Vatican calls "life" issues," including abortion rights. Vatican spokesperson the Rev. Federico Lombardi said that the pope told him how Obama "explicitly expressed his commitment to reducing the number of abortions and to listen to the Church"s concerns on moral issues" (Israely, Time, 7/10). According to White House deputy national security aide Denis McDonough, Obama was "eager to find common ground on these issues and to work aggressively to do that" (Simpson/Feller, AP/Boston Globe, 7/11). However, "[I]t may just be that there"s issues that you can"t come to agreement on," McDonough added, noting that Obama believes that "you can disagree without being disagreeable" (Los Angeles Times, 7/11).Montsignor Georg Ganswein, the pope"s personal secretary, said that Obama was given a copy of "Dignitas Personae," or "The Dignity of a Person," a Vatican document released in December detailing the Roman Catholic Church"s most recent stance on bioethics issues (Time, 7/10). The document "hardened" the Church"s opposition to embryonic stem cell research, cloning and in vitro fertilization (AP/Boston Globe, 7/11). Obama assured the pope he would read the document that day on his flight from Italy to Ghana. Ganswein said that the document "can help the president better understand the position of the Catholic Church." Lombardi noted that it "would be ambiguous to hide or minimize what we believe," adding, "It"s not meant to be divisive or polemical" (Time, 7/10).

"Nature" And "Nurture" Variables Early Predictors Of AMD
Like many diseases, causes for age-related macular degeneration (AMD) can be categorized as either "nature" or "nurture". Researchers think these factors, when used in the proper model, can be strong predictors of the disease.
News of the day
The Preclinical Natural History Of Serous Ovarian Cancer: Defining The Target For Early Detection
Ovarian cancer kills approximately 15,000 women in the United States every
Oncology

Diamyd(R) Phase III Study Approved For Younger Patients In The US

Diamyd Medical reported that the company has received approval from the US Food and Drug Administration (FDA) to include children with type 1 diabetes from 10 years of age in the company"s Phase III study with the diabetes vaccine Diamyd(R). Diamyd Medical is conducting two parallel phase III studies, one in Europe and one in the USA, comprising a total of 640 patients. The objective of the studies is to evaluate the ability of the Diamyd(R) vaccine to halt or delay the autoimmune attack on the body"s insulin-producing cells, thereby preserving the body"s own ability to produce insulin in children and adolescents with recent-onset type 1 diabetes. The European study, which is being conducted in nine countries, is approved for patients between 10 and 20 years of age, whilst the US study so far has been approved only for patients 16 to 20 years, an age group with few recent-onset type 1 diabetes patients. The company is, with the new approval, allowed to begin enrollment of children from 10 years of age in the US phase III study. "This is a big step forward giving us the opportunity to accelerate patient recruitment in the US," says Elisabeth Lindner, President and CEO of Diamyd Medical. "We are pleased that the approval comes now in connection with the world"s largest diabetes conference, the ADA"s 69th Scientific Sessions, which is currently ongoing in New Orleans." The company will now, in pace with Institutional Review Board (IRB) approvals in USA, increase the number of American pediatric clinics in the study. The application for market approval is, as before, planned for spring 2011. Diamyd Medical is represented at booth #2431 at the ADA"s 69th Scientific Sessions in New Orleans, USA. About Diamyd Medical Diamyd Medical is a Swedish biopharmaceutical company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. The company"s most advanced project is the GAD-based drug Diamyd(R) for type 1 diabetes. Phase III trials for this drug are in progress in both Europe and the US. In addition, the company has started clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson"s disease. The company has currently three clinical-phase products. Diamyd Medical has offices in Sweden and in the US. Shares are listed on the Nasdaq OMX Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements Diamyd Medical AB (publ)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009